子宫内膜Pipelle取样失败相关的患者与提供者因素
研究连续纳入2013年1月至6月期间在一大型医疗系统内因疑似子宫病变行Pipelle活检的201例患者记录,分析取样失败的危险因素。取样失败46例(22.89%),其中无法进入子宫内膜8例(17.39%)、样本不足37例(80.43%)、原因不明1例(2.18%)。与失败相关的因素包括绝经后出血作为活检指征(OR 7.41,95%CI 2.27-24.14)、既往活检失败史(OR 23.87,95%CI 3.76-151.61)及提供者类型(医师 vs 中级提供者)(OR 9.152,95%CI 2.49-33.69)。
要点
- Pipelle活检取样失败率为22.89%(46/201),其中样本不足占80.43%。
- 绝经后出血作为活检指征与取样失败相关(OR 7.41,95%CI 2.27-24.14)。
- 既往活检失败史(OR 23.87,95%CI 3.76-151.61)和医师操作(vs 中级提供者)(OR 9.152,95%CI 2.49-33.69)与取样失败相关。
核心结论
- 研究识别了Pipelle活检失败的若干危险因素,提示对具有特定特征(包括绝经后出血和既往Pipelle活检失败史)的女性进行Pipelle取样时需特别谨慎。
- 基于个人和临床数据的取样失败风险显著升高,提示提供者必须考虑额外因素以提高取样成功率。
研究设计与样本
- 连续选取2013年1月至2013年6月6个月期间在一大型医疗系统内因疑似子宫病变行Pipelle活检的201例患者记录。
- 从医疗记录中提取年龄、BMI、孕产次及既往Pipelle活检史等个人和医疗数据。
- 采用逻辑回归分析确定与活检取样失败相关的因素。
主要发现
- 201例女性中Pipelle活检取样失败46例(22.89%)。
- 失败原因中,无法进入子宫内膜8例(17.39%),样本不足37例(80.43%),原因不明1例(2.18%)。
- 与取样失败相关的个人和医疗因素包括:绝经后出血作为活检指征(OR 7.41,95%CI 2.27-24.14);既往活检失败史(OR 23.87,95%CI 3.76-151.61);提供者类型(医师 vs 中级提供者)(OR 9.152,95%CI 2.49-33.69)。
临床怎么用
- 作者认为,对具有绝经后出血和既往Pipelle活检失败史等特定特征的女性,进行Pipelle取样时需特别谨慎。
- 作者认为,提供者必须考虑额外因素以提高取样成功率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore risk factors associated with sampling failure in women who underwent Pipelle biopsy. METHODS: A consecutive sample of 201 patient records was selected from women who underwent Pipelle biopsy procedures for suspected uterine pathology in a large healthcare system over a 6-month period (January 2013 through June 2013). Personal and medical data including age, BMI, gravidity and parity, and previous history of Pipelle biopsy were abstracted from medical records for each patient. Logistic regression analyses were used to determine factors associated with biopsy sampling failure. RESULTS: Pipelle biopsy sampling failed in 46 out 201 women (22.89%), where 8 (17.39%) were due to inability to access the endometrium, 37 (80.43%) were inadequate samples, and 1 (2.18%) was due to unknown reasons. Personal and medical factors found to be related to sampling failure included: postmenopausal bleeding as biopsy indication (OR 7.41, 95% CI 2.27-24.14); history of prior biopsy failure (OR 23.87, 95% CI 3.76-151.61); and provider type (physician vs. midlevel provider) (OR 9.152, 95% CI 2.49-33.69). CONCLUSION: We identified several risk factors for biopsy failure that suggest the need for particular care with Pipelle sampling procedures among women with certain characteristics, including postmenopausal bleeding and a history of prior failed Pipelle biopsy. Our finding of a significantly higher risk of sampling failure based on personal and clinical data suggests that providers must take into account additional considerations to improve sampling success.
引用
- Adambekov S, Goughnour SL, Mansuria S, et al. Patient and provider factors associated with endometrial Pipelle sampling failure. Gynecol Oncol. 2016. PMID: 27912906. doi:10.1016/j.ygyno.2016.11.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。